Citadel Advisors’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-42,400
| Closed | -$1.44M | – | 14004 |
|
|
2025
Q4 | $1.44M | Buy |
42,400
+31,976
| +307% | +$993K | ﹤0.01% | 6615 |
|
|
2025
Q3 | $269K | Buy |
+10,424
| New | +$136K | ﹤0.01% | 10611 |
|
|
2025
Q2 | – | Sell |
-5,163
| Closed | -$50.4K | – | 14623 |
|
|
2025
Q1 | $50.4K | Sell |
5,163
-2,150
| -29% | -$21.1K | ﹤0.01% | 12305 |
|
|
2024
Q4 | $92.4K | Buy |
7,313
+4,113
| +129% | +$52.2K | ﹤0.01% | 11593 |
|
|
2024
Q3 | $51.5K | Sell |
3,200
-6,638
| -67% | -$134K | ﹤0.01% | 11877 |
|
|
2024
Q2 | $240K | Sell |
9,838
-400
| -4% | -$18.5K | ﹤0.01% | 9564 |
|
|
2024
Q1 | $735K | Sell |
10,238
-25,362
| -71% | -$3.53M | ﹤0.01% | 7562 |
|
|
2023
Q4 | $7.08M | Buy |
35,600
+1,987
| +6% | +$246K | ﹤0.01% | 3307 |
|
|
2023
Q3 | $4.47M | Buy |
33,613
+1,163
| +4% | +$190K | ﹤0.01% | 3842 |
|
|
2023
Q2 | $4.85M | Sell |
32,450
-413
| -1% | -$64.3K | ﹤0.01% | 3698 |
|
|
2023
Q1 | $4.82M | Sell |
32,863
-17,225
| -34% | -$3.48M | ﹤0.01% | 3875 |
|
|
2022
Q4 | $7.93M | Buy |
50,088
+625
| +1% | +$100K | ﹤0.01% | 3147 |
|
|
2022
Q3 | $9.52M | Buy |
49,463
+200
| +0.4% | +$37.8K | ﹤0.01% | 2846 |
|
|
2022
Q2 | $7.19M | Buy |
49,263
+47,750
| +3,156% | +$6.36M | ﹤0.01% | 3158 |
|
|
2022
Q1 | $266K | Sell |
1,513
-850
| -36% | -$161K | ﹤0.01% | 10865 |
|
|
2021
Q4 | $694K | Sell |
2,363
-1,300
| -35% | -$347K | ﹤0.01% | 8865 |
|
|
2021
Q3 | $910K | Sell |
3,663
-10,275
| -74% | -$2.72M | ﹤0.01% | 8396 |
|
|
2021
Q2 | $3.54M | Buy |
13,938
+10,150
| +268% | +$1.9M | ﹤0.01% | 5225 |
|
|
2021
Q1 | $673K | Buy |
3,788
+913
| +32% | +$151K | ﹤0.01% | 9031 |
|
|
2020
Q4 | $454K | Buy |
+2,875
| New | +$625K | ﹤0.01% | 8325 |
|
Citadel Advisors's RAPT Position: Q1 2026 in Review
Citadel Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 591,802 shares — an estimated $20M sold.
Citadel Advisors first reported a position in RAPT in Q3 2021 and held it in 14 quarters. The position peaked at $20M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Citadel Advisors reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 591,802 RAPT Therapeutics shares in Q1 2026, an estimated $20M.
- Citadel Advisors first reported a position in RAPT Therapeutics in Q3 2021 and held it in 14 quarters.
- Citadel Advisors's RAPT Therapeutics position peaked at $20M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.